'The decision is clear': Curis cuts workforce as pending data hint at near-term FDA application

Curis had some tough decisions to make to ensure its leukemia drug could survive, but the data were clear: The company needed to rally behind the med, and, in today’s biotech landscape, that means layoffs and a slimming of other programs.